drugset / Trial / NCT00332020

Regulation of Coagulation in Orthopedic Surgery to Prevent DVT and PE, a Controlled, Double-blind, Randomized Study of BAY 59-7939 in the Extended Prevention of VTE in Patients Undergoing Elective Total Hip Replacement

NCT00332020

Phase 3 Completed 2457 enrolled Bayer
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to assess if 10 mg BAY 59-7939, taken once daily as a tablet, is safe and can help prevent blood clots forming after a hip replacement operation.

Timeline

Start
2006-02
Primary completion
2007-05
Completion
2007-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Enoxaparin sodium Other / unclassified 40 mg Subcutaneous
Subject Rivaroxaban Other / unclassified 10 mg Oral